Company intelligence / Profile preview

ALSA

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

ALSA Ventures is a London-based venture capital firm investing in early-stage novel therapeutics in biotechnology and pharmaceuticals. It has raised a $59M fund (first close) targeting $150M total, with portfolio companies including Epsilogen, Oxford BioTherapeutics, Montis Biosciences, and Promatix Biosciences (launched by ALSA). Also launched Eclipse, a clinical accelerator for late preclinical assets.

Industry: Investors

Partnerships

LonzaICON

Beyond the preview

Go deeper on ALSA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALSA.

Explore the full profile